Hepatitis C Community
a little Roche data
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

a little Roche data

"ZURICH, Nov 2 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX: Quote, Profile, Research) says it has moved its investigational hepatitis C drug R1626 into a new mid-stage trial after it showed promising results in combination with two of its other medicines.

Roche said on Friday the hepatitis C virus could no longer be detected in up to 81 percent of patients after four weeks of treatment with R1626, in combination with Pegasys and Copegus.

Based on the results of the Phase IIa study, Roche will move R1626 into a Phase IIb trial.

In a separate statement on Friday Roche also said a Pegasus and Copegus combination had shown benefits in patients who did not respond to initial treatment with Schering Plough Corp's (SGP.N: Quote, Profile, Research) Pegintron."
Related Discussions
5 Comments Post a Comment
Blank
233616_tn?1312790796
Blank
233616_tn?1312790796
woo hoo...the race is on, better than teleprivir....by 6 percent....hope the numbers are right.

has anyone toyed with extra zinc for it's replication inhibiting qualities? it's cheap and known to inhibit virus's.
Blank
264121_tn?1313033056
Do you have any idea what the dosage levels of the combo of pegasys/riba and alinia were in the trials and for how long the subjects were treated?
Blank
Avatar_m_tn
article came out latter, a tiny bit more detail

"Roche Issues Hepatits Drug Data
By Elizabeth Trotta
Staff Reporter
11/2/2007 6:00 PM E

"Roche said Friday that in a phase IIa study a triple-drug combination for treatment of hepatitis C showed a robust virological response and subsequently will proceed to a phase IIb study.
Presenting results at the American Association of the Study of Liver Diseases (AASLD) meeting in Boston, the Swiss drugmaker said its investigational hepatitis C drug R1626 showed promising antiviral activity in the phase IIa trial when given with Pegasys (peginterferon alfa-2a) and Copegus. The aforementioned Roche drugs are used together to treat adults with chronic hepatitis C whose liver still works normally and who haven't been previously treated with an interferon alpha.

After four weeks of treatment with the three-drug combination, the virus couldn't be detected in 81% of patients with a mean decrease in viral load of 5.2 log10 from the baseline, and Roche said most adverse events were mild to moderate.

((((((((Also, no resistance to R1626 was identified following intensive testing for either two weeks of treatment with R1626 as monotherapy or in patients treated with R1626 for four weeks in combination with the standard of care. +++thought this was important)))))))))

The phase IIb study, called POLI 1, which will further investigate R1626 in ((((((((combination with standard or lower dose of Pegasys and standard dose of Copegus++++doesn't look like their interested in the lowering of riba dose)))))))), is now open and enrolling patients in eight countries, including the U.S.
Pharmasset , which partners with Roche to develop chronic hepatitis C drug R7128, presented data Friday on a phase I 14-day monotherapy study of patients who failed to respond to standard therapy. Pharmassest said there was a 99% mean decrease in HCV (((((((with no serious adverse events. ++++++important))))))))(Pharmasset divulged positive preliminary results for the study in September.) The companies are hoping those results will translate when the drug is used in combination with other therapies for a longer duration in a previously untreated population

alagirl, no Alinia in this trial. I believe peg/riba dosing was standard for the Roche SOC products.

Merrybe, I seem to cross paths with you every morning (4:30 am my time) you must be a late owl, or early owl like me (lol)
Blank
Avatar_n_tn
The only 4 week RVr data from Vertex I have seen was from EASL and showed 88% success measured at less than 30 and 79% at less than 10.  The Roche study doesn't show what measurement they were using.  But their 81% is either 7% worse or 2% better, unless you have some different Vertex data.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
242532_tn?1269553979
Blank
Emotional Eating Control: How to St...
14 hrs ago by Roger Gould, M.D.Blank
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
242532_tn?1269553979
Blank
3 Reasons Why You are Still Binge E...
Jul 14 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
317787_tn?1373214989
Blank
Dee1956
DC
1747881_tn?1358189534
Blank
hrsepwrguy
Greeley, CO
Avatar_f_tn
Blank
susan400
FL
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
446474_tn?1404424777
Blank
HectorSF
CA
766573_tn?1365170066
Blank
Idyllic